US Patent

US8916131 — Radiopharmaceutical composition

Formulation · Assigned to GE Healthcare Ltd · Expires 2028-09-16 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a radiopharmaceutical composition that includes a compound of Formula (I) and polysorbate as an excipient.

USPTO Abstract

The present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a method for the preparation of the radiopharmaceutical composition of the invention as well as particular uses of the radiopharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number
US8916131
Jurisdiction
US
Classification
Formulation
Expires
2028-09-16
Drug substance claim
No
Drug product claim
Yes
Assignee
GE Healthcare Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.